Search research articles
Contact Us
Filters
Showing results (91-100 of 107) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2017
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
Stefan Kommoss, Boris Winterhoff, Ann L Oberg, et al.
Annals of Surgical Oncology
|
November 30, 2016
Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study
Rüdiger Klapdor, Peter Hillemanns, Linn Wölber, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2013
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group
Andreas du Bois, Nina Ewald-Riegler, Nikolaus de Gregorio, et al.
The New England Journal of Medicine
|
December 7, 2021
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer
Philipp Harter, Jalid Sehouli, Ignace Vergote, et al.
Molecular Cancer Therapeutics
|
April 9, 2015
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition
Sally J Davis, Karen E Sheppard, Michael S Anglesio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Rachel N Grisham, Ignace Vergote, Susana Banerjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
The Lancet. Oncology
|
April 3, 2025
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial
Toon Van Gorp, Kathleen N Moore, Gottfried E Konecny, et al.
Geburtshilfe Und Frauenheilkunde
|
December 9, 2020
Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?
Linn Woelber, Mareike Bommert, Katharina Prieske, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Bradley J Monk, Rachel N Grisham, Susana Banerjee, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 107) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2017
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
Stefan Kommoss, Boris Winterhoff, Ann L Oberg, et al.
Annals of Surgical Oncology
|
November 30, 2016
Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study
Rüdiger Klapdor, Peter Hillemanns, Linn Wölber, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2013
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group
Andreas du Bois, Nina Ewald-Riegler, Nikolaus de Gregorio, et al.
The New England Journal of Medicine
|
December 7, 2021
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer
Philipp Harter, Jalid Sehouli, Ignace Vergote, et al.
Molecular Cancer Therapeutics
|
April 9, 2015
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition
Sally J Davis, Karen E Sheppard, Michael S Anglesio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Rachel N Grisham, Ignace Vergote, Susana Banerjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
The Lancet. Oncology
|
April 3, 2025
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial
Toon Van Gorp, Kathleen N Moore, Gottfried E Konecny, et al.
Geburtshilfe Und Frauenheilkunde
|
December 9, 2020
Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?
Linn Woelber, Mareike Bommert, Katharina Prieske, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Bradley J Monk, Rachel N Grisham, Susana Banerjee, et al.
Page
of 11